iBio Introduces MUC16 as its Latest Immune-Oncology Target Program

(24/7 MARKET NEWS) –  iBio, Inc. (NASDAQ: IBIO) disclosed, after yesterday’s market close, that MUC16 potentially offers a differentiated and effective tool in the fight against cancer and is the target of its latest immune-oncology program.

iBio is at $1.65, up $0.8998 (+119.94%), on trading volume of 2 million premarket shares.

Its 52-week trading range is $0.36 to $16.51. It’s cleared all of its recent resistance levels and looks like it wants to continue to run. If it can break through this morning’s $2.06 premarket high, on massive volume,it’s setup is ideal for a run to the $8 range, but that run is very unlikely to happen today.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist